Evidence map›Paper›PMID 31156704›Full record

ArticleFrontiers in genetics2019

Identification of Cancer Dysfunctional Subpathways by Integrating DNA Methylation, Copy Number Variation, and Gene-Expression Data.

Siyao Liu, Baotong Zheng, Yuqi Sheng, Qingfei Kong, Ying Jiang, Yang Yang, Xudong Han, Liang Cheng, Yunpeng Zhang, Junwei Han

Open access · goldAbstract read
In one paragraph

Article in Frontiers in genetics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.7field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. RF-PseU: A Random Forest Predictor for RNA Pseudouridine Sites.Frontiers in bioengineering and biotechnology · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Siyao LiuCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China.
Baotong ZhengCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China.
Yuqi ShengCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China.
Qingfei KongCollege of Basic Medical Science, Harbin Medical University, Harbin, China.
Ying JiangCollege of Basic Medical Science, Heilongjiang University of Chinese Medicine, Harbin, China.
Yang YangCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China.
Xudong HanCollege of Basic Medical Science, Harbin Medical University, Harbin, China.
Liang ChengCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China.
Yunpeng ZhangCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China.
Junwei HanCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China.
Harbin Medical University · CNHeilongjiang University of Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A subpathway is defined as the local region of a biological pathway with specific biological functions. With the generation of large-scale sequencing data, there are more opportunities to study the molecular mechanisms of cancer development. It is necessary to investigate the potential impact of DNA methylation, copy number variation (CNV), and gene-expression changes in the molecular states of oncogenic dysfunctional subpathways. We propose a novel method, Identification of Cancer Dysfunctional Subpathways (ICDS), by integrating multi-omics data and pathway topological information to identify dysfunctional subpathways. We first calculated gene-risk scores by integrating the three following types of data: DNA methylation, CNV, and gene expression. Second, we performed a greedy search algorithm to identify the key dysfunctional subpathways within pathways for which the discriminative scores were locally maximal. Finally, a permutation test was used to calculate the statistical significance level for these key dysfunctional subpathways. We validated the effectiveness of ICDS in identifying dysregulated subpathways using datasets from liver hepatocellular carcinoma (LIHC), head-neck squamous cell carcinoma (HNSC), cervical squamous cell carcinoma, and endocervical adenocarcinoma. We further compared ICDS with methods that performed the same subpathway identification algorithm but only considered DNA methylation, CNV, or gene expression (defined as ICDS_M, ICDS_CNV, or ICDS_G, respectively). With these analyses, we confirmed that ICDS better identified cancer-associated subpathways than the three other methods, which only considered one type of data. Our ICDS method has been implemented as a freely available R-based tool (https://cran.r-project.org/web/packages/ICDS).

Indexed as

copy number variationDNA methylationmulti-omics datapathway topological informationsubpathway activity

Identifiers

PMID31156704
PMCPMC6529853
OpenAlexW2945047839

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.